Eli Lilly: Still Much Room To Ride The Weight-Loss Wave
Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...
FDA Approves Weight-loss Drug Zepbound For Sleep Apnea – Will Insurance Cover This $1000-Per-Month Medication?
The U.S. Food and Drug Administration (FDA) recently approved Zepbound® (tirzepatide) as the first prescription medication for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with ...
pharmaphorum21h
Mounjaro cleared for NHS use, but patients may have to wait
It could take up to 12 years for Mounjaro (tirzepatide) to become available for everyone who fulfils the criteria set by cost-effectiveness agency NICE in its recommendation (PDF) – adults who ...
Flow Space on MSN18h
The Latest Science About GLP-1 Drugs & Weight Loss
Semaglutide is helping patients achieve weight loss previously achievable only with bariatric surgery. But at what cost?
aha.org23h
Report: Prices for top Medicare Part D drugs nearly doubled since entering the market
Prices for the top 25 brand-name Medicare Part D drugs have increased by an average of 98% since entering the market, ...